Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women’s Health Initiative

References

• Sung H, Siegel RL, Torre LA, Pearson-Stuttard J, Islami F, Fedewa SA, Goding Sauer A, Shuval K, Gapstur SM, Jacobs EJ, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin. 2019;69(2):88–112.
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423
   PubMed Web of Science ®Google Scholar
• Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, Poole EM, Lu W, Holmes MD, Quesenberry CP, Jr., et al. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res Treat. 2012;132(2):729–39. doi:10.1007/s10549-011-1914-3
   PubMed Web of Science ®Google Scholar
• Schmitz KH, Neuhouser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT, Drake BF. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013;105(18):1344–54. doi:10.1093/jnci/djt223
   PubMedGoogle Scholar
• Prizment AE, Flood A, Anderson KE, Folsom AR. Survival of women with colon cancer in relation to precancer anthropometric characteristics: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2229–37. doi:10.1158/1055-9965.EPI-10-0522
   PubMed Web of Science ®Google Scholar
• McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, Pescatello LS, Bloodgood B, Tennant B, Vaux-Bjerke A, 2018 Physical Activity Guidelines Advisory Committee*, et al. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exerc. 2019;51(6):1252–61. doi:10.1249/MSS.0000000000001937
   PubMed Web of Science ®Google Scholar
• Liu H, Liu JY, Wu X, Zhang JT. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol. 2010;1(1):69–89.
   PubMedGoogle Scholar
• Lenhard JM. Lipogenic enzymes as therapeutic targets for obesity and diabetes. Curr Pharm Des. 2011;17(4):325–31.
   PubMed Web of Science ®Google Scholar
• Boizard M, Le Liepvre X, Lemarchand P, Foufelle F, Ferre P, Dugail I. Obesity-related overexpression of fatty-acid synthase gene in adipose tissue involves sterol regulatory element-binding protein transcription factors. J Biol Chem. 1998;273(44):29164–71. doi:10.1074/jbc.273.44.29164
   PubMed Web of Science ®Google Scholar
• Kusunoki J, Kanatani A, Moller DE. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. ENDO. 2006;29(1):91–100. doi:10.1385/ENDO:29:1:91
   Google Scholar
• Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem. 2000;48(5):613–22. doi:10.1177/002215540004800505
   PubMed Web of Science ®Google Scholar
• Montesdeoca N, Lopez M, Ariza X, Herrero L, Makowski K. Inhibitors of lipogenic enzymes as a potential therapy against cancer. Faseb J. 2020;34(9):11355–81. doi:10.1096/fj.202000705R
   PubMed Web of Science ®Google Scholar
• Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006;66(10):5287–94. doi:10.1158/0008-5472.CAN-05-1489
   PubMed Web of Science ®Google Scholar
• Liu H, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther. 2008;7(2):263–70. doi:10.1158/1535-7163.MCT-07-0445
   PubMed Web of Science ®Google Scholar
• Fhu CW, Ali A. Fatty acid synthase: An emerging target in cancer. Molecules. 2020;25(17):3935. doi:10.3390/molecules25173935
   PubMed Web of Science ®Google Scholar
• Porta R, Blancafort A, Casoliva G, Casas M, Dorca J, Buxo M, Vinas G, Oliveras G, Puig T. Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients. Menopause. 2014;21(2):188–91. doi:10.1097/GME.0b013e31829d17dc
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med. 1989;321(10):636–41. doi:10.1056/NEJM198909073211003
   PubMed Web of Science ®Google Scholar
• Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77(3):474–82. doi:10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K
   PubMed Web of Science ®Google Scholar
• Giro-Perafita A, Sarrats A, Perez-Bueno F, Oliveras G, Buxo M, Brunet J, Vinas G, Miquel TP. Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. Oncotarget. 2017;8(43):74391–405. doi:10.18632/oncotarget.20152
   PubMedGoogle Scholar
• Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. JCO. 2008;26(35):5713–20. doi:10.1200/JCO.2008.18.2675
   PubMed Web of Science ®Google Scholar
• Wysham WZ, Roque DR, Han J, Zhang L, Guo H, Gehrig PA, Zhou C, Bae-Jump VL. Effects of fatty acid synthase inhibition by Orlistat on proliferation of endometrial cancer cell lines. Target Oncol. 2016;11(6):763–9. doi: 10.1007/s11523-016-0442-9. PMID: 27188391.
   PubMed Web of Science ®Google Scholar
• Fako VE, Wu X, Pflug B, Liu JY, Zhang JT. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J Med Chem. 2015;58(2):778–84. doi:10.1021/jm501543u
   PubMed Web of Science ®Google Scholar
• Madka V, Kumar G, Pathuri G, Panneerselvam J, Zhang Y, Ganta V, Lightfoot S, Lubet R, Suen CS, Steele VE, et al. Proton pump inhibitor omeprazole suppresses carcinogen-induced colonic adenoma progression to adenocarcinoma in F344 rat. Cancer Prev Res (Phila). 2021;14(11):1009–20.
   PubMed Web of Science ®Google Scholar
• Halfdanarson OO, Fall K, Ogmundsdottir MH, Lund SH, Steingrimsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: an Icelandic population-based case-control study. Pharmacoepidemiol Drug Saf. 2019;28(4):471–8. doi:10.1002/pds.4702
   PubMed Web of Science ®Google Scholar
• Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(10):1437–56. doi:10.1007/s00228-020-02927-8
   PubMed Web of Science ®Google Scholar
• Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One. 2017;12(12):e0189114. doi:10.1371/journal.pone.0189114
   PubMed Web of Science ®Google Scholar
• Group TWsHIS Design of the women's health initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998;19(1):61–109.
   PubMedGoogle Scholar
• Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. Implementation of the women's health initiative study design. Ann Epidemiol. 2003;13(9 Suppl):S5–S17. doi:10.1016/S1047-2797(03)00043-7
   PubMed Web of Science ®Google Scholar
• Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, et al. Inhibiting fatty acid synthase with omeprazole to improve efficacy of neoadjuvant chemotherapy in patients with operable TNBC. Clin Cancer Res. 2021;27(21):5810–7. doi:10.1158/1078-0432.CCR-21-0493
   PubMed Web of Science ®Google Scholar
• Vargas AJ, Neuhouser ML, George SM, Thomson CA, Ho GY, Rohan TE, Kato I, Nassir R, Hou L, Manson JE. Diet quality and colorectal cancer risk in the women's health initiative observational study. Am J Epidemiol. 2016;184(1):23–32. doi:10.1093/aje/kwv304
   PubMed Web of Science ®Google Scholar
• Patlolla JM, Zhang Y, Li Q, Steele VE, Rao CV. Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats. Int J Oncol. 2012;40(1):170–5.
   PubMed Web of Science ®Google Scholar
• Janakiram NB, Mohammed A, Patlolla JMR, Zhang Y, Biddick L, Madka V, Qian L, Lightfoot S, Dunn B, Lubet R, et al. Abstract 5260: NGS Transcriptome analysis of colon adenocarcinomas treated with individual and combination of aspirin and omeprazole. Cancer Research. 2017;77(13_Supplement):5260– doi:10.1158/1538-7445.AM2017-5260
   Google Scholar
• Mohammed A, P JMR, Zhang Y, Biddick L, Madka V, Li Q, Lightfoot S, Lubet R, Suen CS, Steele VE, et al. Omeprazole alone, or in combination with Aspirin inhibits azoxymethane-induced colon adenoma progression to adenocarcinoma and carcinoma invasion in F344 rat model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18–22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015. 75(15 Suppl): Abstract no. 2820. doi:10.1158/1538-7445.AM2015-2820
   Google Scholar
• Brasky TM, Liu J, White E, Peters U, Potter JD, Walter RB, Baik CS, Lane DS, Manson JE, Vitolins MZ, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. Int J Cancer. 2014;135(8):1869–83. doi:10.1002/ijc.28823
   PubMed Web of Science ®Google Scholar
• Zeng R, Cheng Y, Luo D, Wang J, Yang J, Jiang L, Zhuo Z, Guo K, Wu H, Leung FW, et al. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer. 2021;156:190–201. doi:10.1016/j.ejca.2021.07.030
   PubMed Web of Science ®Google Scholar
• Singh S, Karthikeyan C, Moorthy N. Recent advances in the development of fatty acid synthase inhibitors as anticancer agents. Mini Rev Med Chem. 2020;20(18):1820–37. doi:10.2174/1389557520666200811100845
   PubMed Web of Science ®Google Scholar
• Jin UH, Lee SO, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer. 2014;14:498. doi:10.1186/1471-2407-14-498
   PubMed Web of Science ®Google Scholar
• He J, Shi XY, Li ZM, Pan XH, Li ZL, Chen Y, Yan SJ, Xiao L. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer. BMC Mol Cell Biol. 2019;20(1):49.
   PubMed Web of Science ®Google Scholar
• Song T, Jeon HK, Hong JE, Choi JJ, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW. Proton pump inhibition enhances the cytotoxicity of paclitaxel in cervical cancer. Cancer Res Treat. 2017;49(3):595–606. doi:10.4143/crt.2016.034
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee CZ, Lin YC, Kao LT, Lin HC. Negative association of proton pump inhibitors with subsequent development of breast cancer: A nationwide population-based study. J Clin Pharmacol. 2019;59(3):350–5. doi:10.1002/jcph.1329
   PubMed Web of Science ®Google Scholar
• Ding DC, Sung FC, Chen W, Wang JH, Lin SZ. Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study. Breast J. 2020;26(3):474–8. doi:10.1111/tbj.13519
   PubMed Web of Science ®Google Scholar
• Wang CJ, Li D, Danielson JA, Zhang EH, Dong Z, Miller KD, Li L, Zhang JT, Liu JY. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting ­fatty acid synthase. Cancer Lett. 2021;509:1–12. doi:10.1016/j.canlet.2021.03.026
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J, et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015;107(8). doi:10.1093/jnci/djv147
   PubMedGoogle Scholar
• Soto-Pantoja DR, Gaber M, Arnone AA, Bronson SM, Cruz-Diaz N, Wilson AS, Clear KYJ, Ramirez MU, Kucera GL, Levine EA, et al. Diet alters entero-mammary signaling to regulate the breast microbiome and tumorigenesis. Cancer Res. 2021;81(14):3890–904. doi:10.1158/0008-5472.CAN-20-2983
   PubMed Web of Science ®Google Scholar
• Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M. Hypergastrinemia. Gastroenterol Rep (Oxf). 2015;3(3):201–8. doi:10.1093/gastro/gov004
   PubMed Web of Science ®Google Scholar
• Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, et al. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer. 2020;123(5):844–51. doi:10.1038/s41416-020-0939-y
   PubMed Web of Science ®Google Scholar
• Zuo Y, Jing Z, Bie M, Xu C, Hao X, Wang B. Association between Helicobacter pylori infection and the risk of colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). ) 2020;99(37):e21832. doi:10.1097/MD.0000000000021832
   PubMed Web of Science ®Google Scholar
• Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818–31. doi:10.1001/jama.2015.13766
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017;21(11):1001–16. doi:10.1080/14728222.2017.1381087
   PubMed Web of Science ®Google Scholar
• Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26(1):47–57. doi:10.1093/annonc/mdu225
   PubMed Web of Science ®Google Scholar